Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
all-trans retinoic acid + cisplatin + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Instituto Nacional de Cancerologia de Mexico
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of all-trans retinoic acid (ATRA), cisplatin, and paclitaxel. ATRA is a vitamin A derivative that promotes cell differentiation and has anti-cancer properties. Cisplatin is a platinum-based chemotherapy that damages DNA, while paclitaxel is a taxane that stabilizes microtubules. This combination has shown synergistic effects in treating advanced non-small cell lung cancer, with ATRA potentially preventing chemotherapy-related tumor-initiating cell enrichment and sensitizing cancer stem cells to cisplatin treatment.
02
Targets
MicrotubuleRAR (Retinoic acid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on all-trans retinoic acid + cisplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on all-trans retinoic acid + cisplatin + paclitaxel.